GlassScriptPhysician profile
John T Ganey
NPI 1215935713
$3,276.37
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,168 · 2021: $473 · 2022: $28.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $294.48 | 2019-2022 | |
| Janssen Biotech, INC. | $240.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $200.32 | 2019-2020 | |
| Celgene Corporation | $189.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $181.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $150.61 | 2019-2021 | |
| Astellas Pharma US INC | $149.86 | 2019 | |
| Amgen INC. | $142.84 | 2019-2021 | |
| Pfizer INC. | $131.24 | 2019-2020 | |
| Genentech USA, INC. | $125.66 | 2019-2020 | |
| Lilly USA, LLC | $117.09 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $103.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $98.61 | 2019-2021 | |
| Epizyme, INC. | $92.37 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $87.04 | 2020-2021 |
Show all 44 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ganey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.